Merrill Goozner, the author of the author of The $800 Million Pill: The Truth Behind the Cost of New Drugs, questions the assumption that a greater push toward compliance has reduced off-label drug promotion in an editorial in MassDevice.
Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn't mean they aren't still promoting the drugs.
Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions
Following the news of the $3 billion settlement between the government and GlaxoSmithKline for illegal promotion of prescription drugs for unapproved uses, Mr. Goozner say many assume off-label promotion will become a thing of the past. However, he wrote, just because companies are more focused on compliance with the law doesn't mean they aren't still promoting the drugs.
Related Articles on Pharmaceuticals:
AMA Adopts New Policy for Drug Shortages
Senate Proposal Would Allow FDA to Fast Track Drugs for Unmet Needs
10 Recent FDA Drug and Medical Device Decisions